SCHEMBL29544780

SCHEMBL29544780

COc1cc2nccc(-c3nn4c(c3Nc3cccc(Cl)c3OC)C(=O)NCC4)c2cc1[N+](=O)[O-]

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 2/20 0.36
ABCG2 Q9UNQ0 1/20 0.34
ATM Q13315 1/20 0.34
CSF1R P07333 2/20 0.33
PDGFRB P09619 1/20 0.33
PDGFRA P16234 1/20 0.33
KDR P35968 1/20 0.33
ALDH1A1 P00352 1/20 0.33
MAPK1 P28482 1/20 0.33
TYK2 P29597 2/20 0.32
MEN1 O00255 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
MAPT P10636 1/20 0.32
CYP2C9 P11712 1/20 0.32
HPGD P15428 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTT P42858 1/20 0.32
KMT2A Q03164 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29544798 0.92 EGFR (0.38) EGFRABCG2ATMCSF1RPDGFRB
SCHEMBL29545142 0.91 CSF1R (0.39) EGFRCSF1RPDGFRAKDRTYK2
SCHEMBL29545092 0.89 EGFR (0.39) EGFRCSF1RPDGFRAKDRMAPK1
SCHEMBL29544955 0.88 EGFR (0.39) EGFRCSF1RKDRTYK2CCNT1
SCHEMBL29544981 0.87 EGFR (0.36) EGFRCSF1RMAPK1TYK2MAPT
SCHEMBL29544407 0.84 CCNT1 (0.34) EGFRCSF1RTYK2CCNT1CDK9
SCHEMBL29544781 0.84 CCNT1 (0.34) EGFRCSF1RTYK2CCNT1CDK9
SCHEMBL29544735 0.84 CCNT1 (0.34) EGFRTYK2CCNT1CDK9
SCHEMBL29544750 0.84 EGFR (0.40) EGFRCSF1RKDR
SCHEMBL29544881 0.83 ATM (0.38) EGFRABCG2ATMPDGFRBPDGFRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022072634-A1 BICYCLIC COMPOUNDS FOR USE IN THE TREATMENT CANCER SCORPION THERAPEUTICS, INC. (US) 2022-04-07 WO disclosed